Skip to Content

Clinical Highlights

Disclaimers

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA. Anticipated approval in 2020
* DaxibotulinumtoxinA for Injection was formerly known as RT002.

References

  1. Carruthers JD, et al. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45–58. doi:10.1097/PRS.0000000000006327
Back to top